Nitric Oxide Production in MELAS Syndrome

Status Completed

Clinical Trial Summary

Introduction

Baylor College of Medicine and Texas Children's Hospital are recruiting individuals with MELAS syndrome for a clinical study. MELAS syndrome is a mitochondrial disease; patients with this disease have muscle weakness and often develop brain strokes, where blood does not flow normally to different parts of the brain. It is believed that these strokes could be due to decreased production of nitric oxide, a naturally occurring compound important for normal blood vessel function. Nitric oxide is made from arginine and citrulline that are normally found in our bodies.

What is the purpose of this study? The purpose of this study is to measure nitric oxide in individuals with MELAS and see if giving arginine or citrulline will increase the formation of nitric oxide. Nitric oxide is thought to be helpful in preventing strokes. Therefore, if arginine and/or citrulline are shown to increase the formation of nitric oxide, they could be used to prevent or treat the strokes in patients with MELAS syndrome.

Clinical Trial Description

What does the study involve? Individuals with MELAS syndrome will be admitted twice to the General Clinical Research Center (GCRC) at Texas Children's Hospital. Each time they will stay for five days, during which a special diet will be provided. Nitric oxide production will be measured by stable isotopes infusion technique that involves placing small tubes in veins (IV catheter), blood sampling, and injecting a harmless stable isotope. Stable isotopes are forms of normal compounds that can be measured accurately. They are not radioactive and there are no known risks to giving them; they are already part of your body in small amounts.

During the first admission nitric oxide levels will be measured, then arginine supplementation will be provided for 48 hours, after which nitric oxide levels will be re-measured to determine the effect of arginine supplementation. During the second admission, the effect of citrulline supplementation will be measured.

Who can participate in the study? Adults or children affected with MELAS syndrome and carrying the DNA change that causes the condition (3243 A>G mutation) can participate. Adults without MELAS disease will be recruited to participate as control subjects.

How to get more information? Subjects interested in participation or getting more information can contact Dr. Ayman El-Hattab at email: elhattab@bcm.edu, office phone: 832-822-4289, cell phone: 646-660-5666, or pager: 832-824-7243 (5523). ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01339494
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Completed
Phase	Phase 0
Start date	July 2009
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01831934` - Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)	Phase 4
Not yet recruiting	`NCT06013397` - Effectiveness of Ketogenic Diet in MELAS Syndrome	N/A
Completed	`NCT04165239` - The KHENERGYZE Study	Phase 2
Completed	`NCT01603446` - L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome	Phase 2
Completed	`NCT00887562` - Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes	Phase 2
Active, not recruiting	`NCT00068913` - Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome	Phase 2
Completed	`NCT03888716` - A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease	Phase 1
Completed	`NCT04948138` - Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome	N/A
Completed	`NCT03056209` - Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers	Phase 1
Active, not recruiting	`NCT05255328` - Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome	N/A
Recruiting	`NCT02114554` - Mitochondrial nt3243 A>G Mutation in Taiwan	N/A
Recruiting	`NCT05554835` - Global Registry and Natural History Study for Mitochondrial Disorders
Completed	`NCT01252979` - Ketones & Mitochondrial Heteroplasmy	Phase 0
Completed	`NCT00004353` - Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia	N/A
Recruiting	`NCT03952234` - L-Citrulline Dose Finding Safety Study in MELAS	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.